US Senate asks Novartis to shed light on data manipulation allegations
The Swiss pharmaceutical firm Novartis has been asked to provide details regarding possible data inaccuracies for its human gene therapy Zolgensma – the world’s most expensive treatment.
Novartis has been accused of withholding information about manipulated data during early testing of Zolgensma, a one-time $2.1 million (CHF2.1 million) treatment for spinal muscular atrophy (SMA), the leading genetic cause of death in infants. The treatment was approved by the US Food and Drug Administration (FDA) in May.
Novartis said its subsidiary in California began investigating the alleged data manipulation for Zolgensma as soon as it learned about it. The company claims that it shared the information with the FDA as soon as it had the interim conclusions.
The chairman of the US Senate Finance Committee, Chuck Grassley, wants to have access to internal reports and to know exactly when the group became aware of the data manipulation. The Basel-based pharmaceutical giant has until August 23 to shed light on the situation. Novartis has acknowledged receipt of this request.
Despite the allegations, the FDA reported last week that it retains full confidence in the new treatment. However, it plans to take the case to court, as the pharmaceutical group was aware of the problem before receiving the green light to market it at the end of May.
“The agency will use its full authorities to take action, if appropriate, which may include civil or criminal penalties,” said an FDA statement last weekExternal link.
Novartis has blamed several employees of its subsidiary Avexis, but according to several analysts this case could cost it dearly. Zolgensma has yet to receive the green light from authorities in the European Union and Japan.
More
More
Novartis rejects suspected data manipulation in US
This content was published on
Swiss pharma giant Novartis has dismissed criticism that it allegedly withheld information about animal testing data inaccuracies to US authorities.
Swiss justice minister hopes EU reform will reduce irregular migration
This content was published on
The European Union’s (EU) New Pact on Migration and Asylum aims to curb irregular migration within Schengen, Justice Minister Beat Jans said on Tuesday.
Swiss electricity supply outlook positive despite uncertainties
This content was published on
Thanks to well-filled gas stores in Europe and increased availability of French nuclear power, the Swiss Federal Electricity Commission is optimistic.
Finance minister wants Swiss banks to hold more equity
This content was published on
Finance Minister Karin Keller-Sutter has repeated calls for banks and their holdings in subsidiaries abroad to hold more equity.
Telecoms sector kept Swiss competitions regulator busy in 2023
This content was published on
Last year, the Swiss Competition Commission (COMCO) conducted 27 investigations and initiated 17 preliminary investigations.
This content was published on
Although Swiss International Air Lines (SWISS) achieved higher revenue at the start of the year, it suffered a dip in profits.
40,000 signatures against animal testing in Switzerland
This content was published on
Switzerland should do away with “restrictive” animal testing and should become a model for innovative, effective, and pain-free scientific research.
More than 45,000 signatures in favour of federal funding for UNRWA
This content was published on
The Foreign Affairs Committee of the House of Representatives (FAC) is expected to decide on the funding of the UNRWA at the beginning of the week.
This content was published on
At the end of January 2024, 6,881 men and women were behind bars in Switzerland. Almost 95% of all places were occupied, the highest number since 2014.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
High pharma margins squeeze health systems
This content was published on
Curing cancer for the masses could be challenging if healthcare systems are crippled by rapidly rising cancer drug prices.
The pharma holy grail: drugs for you, designed by you
This content was published on
In the age of sensors, wearables, and artificial intelligence (AI), almost everything can be customised for the individual.
Push for drug pricing transparency strikes a nerve with industry
This content was published on
The 72nd World Health Assembly opens on Monday, but a draft resolution to end secrecy around drug pricing has already struck a nerve.
Pharma company Sandoz named in US price-fixing lawsuit
This content was published on
The Germany-based subsidiary of Novartis is targeted in a 44-state class action suit for breaching rules on fair competition.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.